News

Mr. Mrha has been vice president of sales and marketing for IVX Animal Health, a member of the Teva Group, based in St. Joseph, Missouri. Marvin Sackner, CEO

MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design of the Phase I clinical study on January 16,

The first funding under the securities purchase agreement between Neoprobe and Montaur is for $7 million, which will be used to repay in full $5.7 million in notes

These payments were necessary in order for Elanco to secure commercialization rights to products for use in poultry and the right to potentially expand commercialization into other food

In this study, Duchenne muscular dystrophy (DMD) patients between 10 and 13 years of age received a single injection of PRO051 (a 2-’O-methyl antisense oligonucleotide) in a small

Mr. Hansen held a number of leadership positions prior to IDSI and most notably served as president of Picker International, a global manufacturer of diagnostic imaging systems, until

In accordance with the study design, in September 2007, an interim analysis of patient response and safety data was conducted based on the first 35 patients enrolled to

Ten healthy adult volunteers were treated with Cellectra device and were asked to report the level of discomfort they experienced immediately after electroporation and at various times thereafter.

Xtent’s CE Mark application includes the Xtent design dossier and the drug formulation submission from Biosensors International Group. Xtent plans to begin European sales of the Custom NX